Professional athlete James Graham appointed to strengthen Advisory Board of Impression for the commercial development of IHL-216A
2020-05-20 00:17:33 (AET) by Ring Zhang 1009
Impression Healthcare Limited (ASX: IHL) announces that professional rugby league footballer James Graham has teamed up with the Company’s advisory board to assist with the commercial development of IHL-216A, one of the company’s flagship drug candidates for the treatment of concussion and traumatic brain injury (TBI).
Cannibis drug developer Impression Healthcare Limited (ASX: IHL) announces that professional rugby league footballer James Graham has teamed up with the Company’s advisory board to assist with the commercial development of IHL-216A, one of the company’s flagship drug candidates for the treatment of concussion and traumatic brain injury (TBI).
James Graham is a popular and celebrated premiership playing professional rugby league footballer who plays as a prop for the St. George Illawarra Dragons in the NRL, and England and Great Britain at international level. He is also a regular media commentator and weekly contributor to the TV program, NRL 360 on Fox Sports.
This is the second appointment of a professional athlete for the IHL-216A development program, following the appointment of former professional AFL player Mr Liam Picken announced last in March this year.
James says he is delighted to join the advisory team, as understanding and treating concussion is something he is incredibly passionate about, and Impression and its IHL-216A program has given him a great platform to contribute to the field.
According to the announcement, as part of the Impression team, James Graham has agreed to offer assistant with the following activities:
the development of ‘real world’ aspects of the clinical program for IHL-216A,
to assist in building Impression’s relationship and concussion solutions with the Rugby League Players Association,
to assist with developing an arrangement with the NRL for the use of IHL-216A throughout the elite competition,
to attend Impression meetings with partners, investors, and program participants, and
to work with Impression to further develop its player wellbeing program.
Speaking of the joining of James, CEO and Managing Director of Impression Joel Latham commented that he has been impressed by James’ extensive knowledge of many aspects of traumatic brain injury and considers James as one of the most respected and influential figures in Australian sport.
Impression also has an extensive clinical program being undertaken for 4 cannabinoid clinical assets, focused on areas of medicine with critical unmet need.
Stock Price Chart
Please click here to check out the latest IHL share price and announcement.
Source from ASX announcement NRL player James Graham joins Impression TBI program